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Abstract The role of K396 in the enzymatic catalysis and the
antigenicity of the 65 kDa isoform of glutamate decarboxylase
(GAD65) was analyzed using the K396R GAD65 mutant.
GAD65 is a major autoantigen in Type 1 diabetes and auto-
antibodies directed to GAD65 are widely used markers for this
disease. We found that (1) recombinant human GAD65 is fully
enzymatically active; (2) the K396R mutation abolished GAD65
activity; and (3) the K396R mutant retained full antigenicity to
GAD65 autoantibodies in serum from Type 1 diabetes patients,
but not to polyclonal antibodies raised to the catalytic
domain. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The decarboxylase reaction of glutamate to generate Q-ami-
nobutyric acid (GABA) and CO2 is catalyzed by glutamate
decarboxylase (GAD) and is assumed to depend on a Schi¡
base formed between cofactor pyridoxal 5-phosphate (PLP)
and a lysine residue (K396) in the active site of the enzyme
[1,2]. The importance of the PLP binding lysine residue in the
active site of other PLP-dependent enzymes was demonstrated
by site-directed mutagenesis studies of aspartate aminotrans-
ferase [3], tryptophan synthase [4], D-amino acid aminotrans-
ferase [5], serine hydroxymethyltransferase [6], ornithine de-
carboxylase [7], and aromatic L-amino acid decarboxylase [8].
65 kDa GAD (GAD65) appears to be a major autoantigen
in Type 1 diabetes [9^11]. Detection of autoantibodies to the
molecule is an essential part of predicting Type 1 diabetes, as
the diagnostic sensitivity of these autoantibodies is 75^85%
[12,13] and GAD65 autoantibodies (GAD65Ab) enable the
discrimination of autoimmune cases in adult-onset diabetes
[14].
Human GAD65 cDNA is used to generate radiolabeled
GAD65 for studies of the importance of this enzyme in
Type 1 diabetes etiology and pathogenesis [15,16]. Immuno-
precipitation of in vitro transcribed and translated radiola-
beled GAD65 is one of the most widely used approaches to
detect GAD65Ab in human serum [17]. However, little is
known to what extent the in vitro transcribed and translated
GAD65 is enzymatically active and if K396 is critical to en-
zyme activity.
It was reported that GAD65 administration or antisense
expression [18^21] in the NOD mouse prevents or delays the
onset of Type 1 diabetes indicating potential use of GAD65 in
prevention of Type 1 diabetes. Production of recombinant
GAD65 is necessary to provide su⁄cient quantities for trials.
Whole-length human GAD65 was expressed in yeast strain
Pichia methanolica [22], Sf9 insect cells [23,24], bacteria [25^
27], and transgenic plants [28] and reported to be enzymati-
cally active.
2. Materials and methods
2.1. Recombinant GAD65
Wild-type human GAD65 cDNA and the GAD65 cDNA carrying
the K396R mutation were inserted into the pcDNAII plasmid (Invi-
trogen, San Diego, CA, USA). Recombinant [35S]GAD65 antigens
were produced by in-vitro-coupled transcription/translation of the re-
spective cDNA with SP6 RNA polymerase and nuclease-treated rab-
bit reticulocyte lysate (Promega, Madison, WI, USA) as described
previously [29,30]. Equal amounts of protein were veri¢ed by densito-
metric analysis of SDS^PAGE. Recombinant human GAD65
(rhGAD65) produced in yeast was kindly donated by ZymoGenetics,
Seattle, WA, USA.
2.2. Site-directed mutagenesis
Site-directed mutagenesis of the PLP binding site of GAD65 was
performed using a commercially available system (Chameleon1 dou-
ble-stranded, site-directed mutagenesis kit, Stratagene, La Jolla, CA,
USA). Brie£y, the p65 plasmid containing the cDNA for human
GAD65 was extended using mutagenesis primer (5P-CGTGGAATC-
CACACCGCATGATGGGAGTCCC-3P), corresponding to nucleo-
tides 1172^1202 of the GAD65 cDNA, containing the codon CGC
for arginine, and a kinase selection primer (5P-CTGTGACTGGTGA-
CGCGTCAACCAAGTC-3P). Transformed colonies were screened
for the desired mutation and the correct DNA sequence con¢rmed
using an ABI prism DNA sequencer.
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2.3. GAD65 activity assay
GAD activity was measured by the 14CO2-trapping method de-
scribed previously [31] with major modi¢cations. rhGAD65 (100 ng)
was incubated with reaction bu¡er (50 mM K2HPO4, 0.03 mM PLP,
0.56 mM L-glutamate, 0.018 WCi 14C-glutamate (Amersham Life Sci-
ence Inc, Arlington Heights, IL, USA), 0.1 mM DTT, pH 6.8) for 1 h
at 37‡C with gentle agitation. During incubation, released 14CO2 was
captured on ¢lter paper (Kontes, Vineland, NJ, USA) soaked in 50 Wl
1 M NaOH. After 1 h incubation, the tubes were removed and placed
on ice for 10 min. The ¢lter paper was then placed in 4 ml of Opti-
£uor scintillation £uid (Packard Biosciences, Torrance, CA, USA)
and the radioactivity was allowed to absorb overnight. The amount
of 14CO2 radioactivity released was counted in a Beckman scintilla-
tion counter. The GAD activity was calibrated with respect to both
incubation time and protein concentration, and expressed as U/mg
protein (1 unit is equal to 1 Wmol of product formed per min at 37‡C).
2.4. GAD65Ab radioimmunoassay (RIA)
GAD65Ab were determined in a RIA, as described previously
[29,30]. Serum samples were tested at a ¢nal serum dilution of 1/25,
unless indicated otherwise. rhGAD65 (ZymoGenetics, Seattle, WA,
USA) was used in the GAD65Ab competitive RIA at the indicated
concentrations.
Antibody positive and negative samples were included in every as-
say to correct for inter-assay variation. Antibody levels were expressed
as a relative index as described previously [29,30]: GAD65Ab in-
dex = (cpm of tested sample3cpm of negative standard)/(cpm of pos-
itive standard3cpm of negative standard). The Juvenile Diabetes
Foundation islet cell autoantibody standard [32], which is also GA-
D65Ab positive as veri¢ed by immunoprecipitation, was used as the
GAD65Ab positive standard [32,33]. A randomly selected control
serum from a healthy volunteer was used as the negative standard.
All samples were tested in duplicate and the coe⁄cient of variations
was determined for each sample. The average intra-assay coe⁄cient of
variation was 9.5 with the highest value of 18 and the lowest being
0.2. The upper limit (index of 0.04) of the normal range was estab-
lished as the 99th percentile of the levels of 182 healthy control sub-
jects.
2.5. Antisera
Two groups of sera from newly diagnosed Type 1 diabetes patients
were used. Group I represents 10 children who were diagnosed with
diabetes at age 7^12 (median 10) and subjected to plasmapheresis [34].
These samples were used in all Immunology of Diabetes Workshops
to standardize islet cell antibodies (ICA) and GAD65Ab [32]. One
sample from this set of 10 samples is serving as the worldwide stan-
dard for expression of ICA levels in JDF units [32] and of GAD65Ab
as a GAD65Ab index [33]. Group II (n = 27) consists of randomly
selected sera from 1^16 year old (median 9) Type 1 diabetes patients.
The subjects were diagnosed at the St. Go«rans Hospital, Sweden,
Stockholm, between 1986 and 1992 [35]. All serum samples were
kept frozen at 380‡C as small aliquots. The study was approved by
the Ethic Committee of the Karolinska Institute, Sweden. All individ-
uals gave their informed consent to participate in the study.
Rabbit antisera were raised by immunization with synthetic pep-
tides corresponding to the PLP binding site of GAD65 [36]. Antisera
5551, 5545, and 5565 were raised towards the amino acid residues
390^404, antisera 5581, 5576, and 5052 were raised towards the amino
acid residues 390^403 of human GAD65.
3. Results
3.1. pH optimum and Km of rhGAD65
Km and pH optimum were determined for rhGAD65 pro-
duced in yeast cells. The pH optimum was observed at 6.8, Km
was calculated at 3.6 mM (Fig. 1, insert). Speci¢c enzyme
activity was found to be 1 U/mg.
3.2. E¡ect of reducing agents and titration of cofactor PLP
DTT and BME were employed to test the e¡ect of reducing
agents on GAD65 enzymatic activity (Fig. 1). Low concen-
trations of DTT and BME (0.1 and 1 mM, respectively),
enhanced the enzymatic activity (40 and 20%, respectively).
At higher concentrations the enzymatic activity decreased
and was completely inhibited at 5 and 100 mM, respectively.
The optimal concentration of the PLP cofactor, titrated at
di¡erent DTT concentrations, was found to be 0.03 mM
(Fig. 1).
3.3. rhGAD65 produced in a cell-free system is enzymatically
active
The enzymatic activity of GAD65 produced by cell-free
transcription/translation was measured at estimated GAD65
concentrations of 55^225 Wg/ml. The pH, cofactor and DTT
concentrations were optimized as above. The speci¢c activity
of GAD65 was found to be 0.68 U/mg (Fig. 2).
3.4. K396R mutant is enzymatically inactive
We substituted K396 with arginine to test the in£uence of
this amino acid substitution on enzyme activity (Fig. 2). While
the wild-type GAD65 showed linear increase of enzyme activ-
ity in relation to protein, no enzymatic activity was detected
for the K396R mutant.
3.5. The antigenicity of the active site is changed by the amino
acid substitution
The possible structural perturbation caused by the K396R
amino acid substitution was probed with polyclonal antibod-
ies raised to 20-mer peptides encompassing the active site [36].
The polyclonal antibodies were tested at di¡erent concentra-
Fig. 1. E¡ects of PLP and reducing agents on rhGAD65 enzyme ac-
tivity. The optimal PLP-cofactor concentration (0.01 mM: light
gray bar; 0.03 mM: dark gray bar; 0.3 mM: white bar; 1.2 mM
PLP: black bar) was determined at di¡erent DTT concentrations
(0.1^10 mM). The e¡ect of BME was tested at di¡erent concentra-
tions (0.1^100 mM) (inserted line plot). Standard errors are indi-
cated. Insert: Lineweaver^Burk plot of rhGAD65.
Fig. 2. Enzyme activity of K396R mutant GAD65. K396R GAD65
(E) and wild-type GAD65 (8) were tested for their enzymatic activ-
ity at the indicated concentrations. Standard errors are indicated.
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tions in a RIA (Fig. 3). Four of the sera (5581, 5545, 5052,
and 5551) show preferred binding to the unmutated molecule
as compared to the K396R mutant. Sera 5576 and 5565
showed equal binding to both molecules.
3.6. K396R mutant retains full antigenicity for antibodies from
Type 1 diabetes patients
Next the antigenicity of the K396R mutant was analyzed
with sera from Type 1 diabetes patients. Sera from 10 Type 1
diabetes patients, used as standards for ICA [37] and GAD-
65Ab [33], were compared for binding capacity to wild-type
and mutated GAD65 (Fig. 4). No signi¢cant di¡erences in
binding to the K396R mutant as compared to wild-type
GAD65 was observed for any of the GAD65Ab positive
sera. Serum samples 898 and 853 were negative for GAD65Ab
as previously demonstrated [29]. Similar results were observed
with sera from 27 consecutively diagnosed Type 1 diabetes
children (Fig. 4, insert B).
3.7. Binding of GAD65Ab from Type 1 diabetes patients to the
K396R mutant can be displaced with RhGAD65
The speci¢city of antibody binding was con¢rmed by dis-
placement of both wild-type GAD65 and the K396R mutant
with unlabeled rhGAD65 (Fig. 4, insert A). Serum sample 622
was incubated with either of the two radiolabeled proteins in
the presence of increasing concentrations of unlabeled
rhGAD65. Both 35S-labeled proteins were equally well dis-
placed from the serum sample. These results con¢rm ¢ndings
that GAD65Ab from Type 1 diabetes patients do not bind to
the active site of the molecule [38].
4. Discussion
Radioactive labeled GAD65 is used in RIAs to detect con-
formation-dependent antibodies directed to this antigen [30].
Hence, it is crucial that the protein is in its native conforma-
tion. The active site of GAD65 is located at amino acid res-
idues 393^396 [39]. Site-directed mutagenesis of the conserved
K396 residue in the active site of GAD65 was undertaken to
con¢rm that this residue is required for enzyme activity. Ar-
ginine was selected to substitute lysine because it is similar in
hydrophobicity and size, while being unable to form a Schi¡
Fig. 3. Polyclonal antibodies raised to peptides representing the ac-
tive site of GAD65 bind wild-type GAD65 signi¢cantly better than
the K396R mutant. Six rabbit polyclonal antibodies (A: 5581;
B: 5052; C: 5576; D: 5545; E: 5551; F: 5565) raised towards pep-
tides representing the active site of GAD65 were tested for their re-
activity to wild-type GAD65 and K396R mutant GAD65 in a RIA.
The sera were tested at the indicated dilutions with both wild-type
GAD65 (E) and mutant (8). The peptide used for immunization is
indicated for each antibody. Cysteine residues introduced to allow
coupling to carrier protein KLH are indicated by an asterisk.
Fig. 4. Binding of mutant GAD65 by sera from Type 1 diabetes patients. Sera from 10 Type 1 diabetes patients were tested for their binding
to mutant GAD65 (E) and wild-type GAD65 (F) in a RIA. The respective GAD65Ab index is indicated for each sample. Insert A: Serum
sample # 622 was further tested in a competition assay. The sample was incubated with the indicated concentrations of rhGAD65 produced in
yeast cells and 35S-labeled mutant GAD65 (E) or wild-type GAD65 (F). The GAD65Ab index observed at no addition of unlabeled antigen
was de¢ned as 100% binding. Insert B: Additional samples (n = 27) of Type 1 diabetes patients were tested for their binding to mutant and
wild-type GAD65 in a RIA. Wild-type GAD65Ab index was plotted against mutant GAD65Ab index. P value for the correlation is indicated
in the ¢gure.
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base. Previous reports of site-directed mutagenesis on PLP-
dependent enzymes substituted lysine with arginine [6,7] dem-
onstrating the usefulness of this amino acid substitution for
the analysis of the role of lysine. The GAD65 K396R muta-
tion resulted in the total loss of enzymatic activity. However,
the molecule retained its full antigenicity to antibodies in sera
of Type 1 diabetes patients while the binding capacity to poly-
clonal antibodies raised towards the active site of the molecule
was signi¢cantly reduced. Competition studies with rhGAD65
suggested that disease-speci¢c antibody epitopes of both mu-
tant and wild-type GAD65 are identical. The high enzyme
speci¢c activity and the immunological characteristics of the
rhGAD65 indicate that the molecule is in its native confor-
mation.
In order to substantiate our major ¢ndings, we report ma-
jor modi¢cations in the 14CO2 trapping method for measuring
the enzymatic activity of GAD65. With this modi¢ed protocol
we tested the enzymatic characteristics of rhGAD65 produced
in yeast and in a cell-free system. The enzymatic activity mea-
sured in our assay for yeast GAD65 (1 U/mg) and GAD65
produced in a cell-free system (0.68 U/mg) correlates well with
the range of reported speci¢c activities for human GAD65;
rhGAD65 expressed in Sf9 insect cells has a speci¢c activity of
0.45 U/mg [23], and rhGAD65 expressed in bacteria has a
speci¢c activity of 1.96 U/mg [27]. We found the pH optima
and Km-values of rhGAD65 to be comparable to previously
reported values for puri¢ed GAD from human brain [40].
The amino acid sequence of GAD65 contains 15 cysteine
residues, all of which are conserved between human, mouse
and rat, suggesting an important role in the tertiary structure
of GAD65. Our data of the e¡ect of reducing agents suggest
that some of the cysteine residues are present in a reduced
state, while others may form disul¢de bridges. The reduction
of the latter results in the loss of the native conformation and
consequently in the loss of enzymatic activity. This observa-
tion is in agreement with recent ¢ndings [2,23] that GAD65
contains sulfhydryl groups prone to oxidation.
This work represents the biochemical characterization of
full length rhGAD65 expressed in yeast cells and by in vitro
transcription and translation. We conclude that rhGAD65
produced in a cell-free transcription and translation system
has immunochemical and enzymatic activities similar to those
reported for the native molecule. We showed by site-directed
mutagenesis that K396 is a crucial amino acid for GAD65
enzymatic activity, however, the structural perturbation of
the K396R mutation does not in£uence the binding of
GAD65Ab from Type 1 diabetes patients. This mutant may
be useful in future studies to analyze PLP and glutamate bind-
ing by GAD65.
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